These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 29779531

  • 1. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM, Rask-Andersen M, Schiöth HB.
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [Abstract] [Full Text] [Related]

  • 2. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C, Lampert A, Hoffmann GF, Ries M.
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Do investors value the FDA orphan drug designation?
    Miller KL.
    Orphanet J Rare Dis; 2017 Jun 19; 12(1):114. PubMed ID: 28629392
    [Abstract] [Full Text] [Related]

  • 5. Investigating the landscape of US orphan product approvals.
    Miller KL, Lanthier M.
    Orphanet J Rare Dis; 2018 Oct 22; 13(1):183. PubMed ID: 30348193
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Incentives for orphan drug research and development in the United States.
    Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J.
    Orphanet J Rare Dis; 2008 Dec 16; 3():33. PubMed ID: 19087348
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR, Xu K, Milto J, Coté TR.
    Discov Med; 2011 Apr 16; 11(59):367-75. PubMed ID: 21524390
    [Abstract] [Full Text] [Related]

  • 12. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul 16; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 13. Orphan Drugs in Oncology.
    Korchagina D, Jaroslawski S, Jadot G, Toumi M.
    Recent Results Cancer Res; 2019 Jul 16; 213():109-142. PubMed ID: 30543010
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V, DeKoven M, Kleinrock M, Wade RL, Kim T, Kaura S.
    Orphanet J Rare Dis; 2016 May 21; 11(1):68. PubMed ID: 27207271
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
    Miller KL, Mueller C, Liu G, Miller Needleman KI, Maynard J.
    Orphanet J Rare Dis; 2020 Sep 03; 15(1):234. PubMed ID: 32883327
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.